Logo image
Use of convalescent plasma for COVID-19 in India: A review & practical guidelines
Journal article   Peer reviewed

Use of convalescent plasma for COVID-19 in India: A review & practical guidelines

Niranjan Shiwaji Khaire, Nishant Jindal, Lakshmi Narayana Yaddanapudi, Suchet Sachdev, Rekha Hans, Naresh Sachdeva, Mini P Singh, Anup Agarwal, Aparna Mukherjee, Gunjan Kumar, …
Indian journal of medical research (New Delhi, India : 1994), Vol.153(1 & 2), pp.64-85
01/2021
DOI: 10.4103/ijmr.IJMR_3092_20
PMID: 33818467
url
https://doi.org/10.4103/ijmr.IJMR_3092_20View
Published (Version of record) Open Access

Abstract

Convalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available. Various CP therapy parameters such as donor selection, antibody quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.
Antibodies, Neutralizing Antibodies, Viral COVID-19 - therapy COVID-19 Serotherapy Humans Immunization, Passive India - epidemiology

Details

Metrics

Logo image